← All trials
NCT03871491
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2019
- Primary completion
- Feb 15, 2022
- Completion date
- Feb 15, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 34000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Child Health and Human Development (NICHD)Lead sponsor
- National Institutes of Health (NIH)Study director
- Boston UniversityCollaborator
- Indiana UniversityCollaborator
- Jawaharlal Nehru Medical CollegeCollaborator
- RTI InternationalCollaborator
- Thomas Jefferson UniversityCollaborator
- University of VirginiaCollaborator
- Aga Khan UniversityCollaborator
- Columbia UniversityCollaborator
- University of Colorado, DenverCollaborator
- University of KinshasaCollaborator
- International Center for Diarrheal Disease ResearchCollaborator
- University of North Carolina at Chapel HillCollaborator
- University of Alabama, BirminghamCollaborator
- Lata Medical Research Foundation, Nagpur, IndiaCollaborator
- Bill and Melinda Gates FoundationCollaborator
- University Teaching Hospital, Lusaka, ZambiaCollaborator
- Moi UniveristyCollaborator
- Institute of Nutrition of Central America and PanamaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.